New hope for PAH patients: early trial tests Easier-to-Use inhaled treatment
NCT ID NCT06429930
Summary
This early-stage study is testing the safety of a new inhaled medication called L608 in healthy volunteers. L608 is being developed as a longer-lasting, easier-to-use version of an existing treatment for pulmonary arterial hypertension (PAH), a serious condition affecting blood vessels in the lungs. The main goal is to see how the body handles different doses and to check for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NZCR Ltd (New Zealand Clinical Research)
RECRUITINGChristchurch, 8011, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.